-
INDIRECT TREATMENT COMPARISONS IN EU JOINT CLINICAL ASSESSMENT: ALIGNED WITH INTERNATIONAL GOOD PRACTICE?
Aug 11, 2026, 17:16 PM -
EFFECTS OF CHINA'S NATIONAL VOLUME-BASED PROCUREMENT ON DRUG AFFORDABILITY, UTILIZATION, AND SUBSTITUTION: A STRUCTURED EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
PROJECTED VS. REAL PHARMACEUTICAL EXPENDITURE IN GERMANY: A RETROSPECTIVE ANALYSIS OF THE PRICE AND VOLUME EFFECTS
Aug 11, 2026, 17:16 PM -
ADVANCING VACCINE VALUE ASSESSMENT THROUGH CROSS-STUDY ANTIBODY KINETICS MODELING: PREDICTING LONG-TERM MENABCWY SEROPROTECTION
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF METHYLONE-ASSISTED THERAPY VERSUS STANDARD OF CARE FOR MODERATE-TO-SEVERE POST-TRAUMATIC STRESS DISORDER: A HYBRID DECISION TREE--MARKOV MODEL
Aug 11, 2026, 17:16 PM -
VALUE-RELEVANT DETERMINANTS OF MEDICATION ADHERENCE IN CARDIAC PATIENTS ACROSS PUBLIC AND PRIVATE HOSPITALS IN NORTHWEST PAKISTAN
Aug 11, 2026, 17:16 PM -
PRODUCTIVITY LOSSES AND HEALTHCARE RESOURCE UTILISATION: A COMPARISON BETWEEN PATIENTS WITH CIDP AND THE GENERAL POPULATION
Aug 11, 2026, 17:16 PM -
THE CAPTURED TRIAL: CAN ALGORITHMS AND QUALITY IMPROVEMENT SUPPORT FOR PRIMARY CARE LEAD TO EARLIER DIAGNOSIS FOR SPECIFIC RARE DISEASE PATIENTS?
Aug 11, 2026, 17:16 PM -
EARLY ECONOMIC EVALUATION OF A PHARMACIST-LED INTERVENTION TO IMPROVE MEDICATION USE IN PATIENTS WITH CHRONIC HEART FAILURE
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF A DYNAMIC CTDNA-GUIDED ADJUVANT STRATEGY IN STAGE II-III COLON CANCER. A SAGITTARIUSMODEL-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
IMMATURE OVERALL SURVIVAL DATA IN FRENCH HTA: WHAT DIFFERENTIATES ASMR III FROM ASMR IV RATINGS?
Aug 11, 2026, 17:16 PM -
REGULATORY APPROVAL AND PATIENT ACCESS TIMELINES IN THE US AND EUROPE: A BASELINE ANALYSIS TO INFORM POTENTIAL EFFECTS OF MOST-FAVOURED-NATION PRICING POLICIES
Aug 11, 2026, 17:16 PM -
BENCHMARKING AI-SUPPORTED EVIDENCE SYNTHESIS TOOLS FOR HEALTH TECHNOLOGY ASSESSMENT (HTA) EVIDENCE GENERATION: A COMPARATIVE ASSESSMENT ACROSS THE EVIDENCE LIFECYCLE
Aug 11, 2026, 17:16 PM -
FROM EUROPEAN JOINT CLINICAL ASSESSMENT TO NATIONAL REIMBURSEMENT: EARLY EXPERIENCE FROM IRELAND
Aug 11, 2026, 17:16 PM -
TRENDS IN PARP INHIBITOR UTILISATION BEFORE AND AFTER REASSESSMENT IN THE NETHERLANDS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ASSESSMENT OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV20) AMONG OLDER ADULTS IN THE PHILIPPINES
Aug 11, 2026, 17:16 PM -
TOWARDS DEVICE-FOCUSED JOINT CLINICAL ASSESSMENT: COMPARING SUBMISSION TEMPLATES FOR MEDICAL DEVICES AND MEDICINAL PRODUCTS
Aug 11, 2026, 17:16 PM -
INFORMING FUTURE FUNDING DECISIONS: A REAL-WORLD COST-EFFECTIVENESS ANALYSIS OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF HOME-BASED CARDIAC REHABILITATION. A SYSTEMATIC REVIEW
Aug 11, 2026, 17:16 PM -
ARTIFICIAL INTELLIGENCE AND HEALTH INEQUITY: A TARGETED LITERATURE REVIEW OF BIAS ARISING FROM HISTORICAL HEALTHCARE DATA (2020-2026)
Aug 11, 2026, 17:16 PM
